Status:

COMPLETED

Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes

Lead Sponsor:

Yale University

Collaborating Sponsors:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Leishmaniasis

Eligibility:

All Genders

18-70 years

Brief Summary

The purpose of this study is to determine what types of cells participate in the defense of humans against Leishmania (skin parasites). People 18-70 years of age who have leishmaniasis, have healed le...

Detailed Description

The purpose of this study is to determine if Th1/Th2 polarization occurs and is linked to the outcome of infection by L. Viannia (asymptomatic, chronic or recurrent infection). This protocol is the fi...

Eligibility Criteria

Inclusion

  • All Groups:
  • \- Age between 18-70 years
  • Inclusion Criteria for the 4 groups for specific objective 1:
  • Historical cases of chronic disease:
  • Historic parasitologically confirmed, skin test positive CL patients who presented chronic CL lesions of \> 6 months duration at the time of diagnosis.
  • No active lesions
  • Voluntary participation in the study
  • Informed consent for HIV testing and participation in the study
  • Historical cases of recurrent disease:
  • Historic CL patients who have developed new parasitologically confirmed lesions after resolution of prior disease
  • No active lesions
  • Voluntary participation in the study
  • Informed consent for HIV testing and participation in the study
  • Asymptomatic infection cases:
  • Resident of endemic area
  • PBMCs responsive to leishmanial antigen in culture
  • No history or evidence of active or prior dermal leishmaniasis
  • Voluntary participation
  • Informed consent for HIV testing and participation in the study
  • Healthy donors:
  • No history or evidence of exposure to transmission of leishmaniasis
  • Voluntary participation
  • Informed consent for HIV testing and participation in the study
  • Inclusion Criteria for the 2 groups for specific objective 2:
  • Chronic disease group:
  • Parasitologically confirmed chronic CL lesions of \> 6 months duration in skin test positive patients.
  • Voluntary participation in the study
  • Informed consent for HIV testing and participation in the study
  • Recurrent disease group:
  • Patients who have developed new parasitologically proven lesions after resolution of prior disease
  • Voluntary participation in the study
  • Informed consent for HIV testing and participation in the study

Exclusion

  • Exclusion criteria all groups:
  • Immunosuppressive disease
  • Pharmacotherapy with drugs that are immunosuppressive
  • Allergy/sensitivity to lidocaine family anesthetics or to latex
  • Pregnancy
  • Breastfeeding
  • Unwillingness to participate

Key Trial Info

Start Date :

December 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 1 2010

Estimated Enrollment :

122 Patients enrolled

Trial Details

Trial ID

NCT00401297

Start Date

December 1 2006

End Date

April 1 2010

Last Update

March 30 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centro Internacional de Entrenamiento e Investigaciones Medicas, CIDEIM

Cali, Colombia